Bayer: Pulmonary Arterial Hypertension trials

The registry lists 19 Pulmonary Arterial Hypertension studies with Bayer as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 2Phase 3 3Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapyCompletedNCT02891850Phase 4Results posted
• Riociguat in Children With Pulmonary Arterial Hypertension (PAH)Active, not recruitingNCT02562235Phase 3Results posted
• BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial HypertensionCompletedNCT00863681Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT00810693Phase 3Results posted
• A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)CompletedNCT04813926
• Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the LungsCompletedNCT03863990
• This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)CompletedNCT03754660Phase 1
• Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial HypertensionCompletedNCT03293407
• Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)CompletedNCT02826252
• Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)CompletedNCT02825160
• Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)CompletedNCT02576002
• A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical PracticeCompletedNCT02545465
• Electronic Activity Level Monitoring Pilot in Pulmonary HypertensionCompletedNCT02536534
• Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)CompletedNCT02428985
• Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)CompletedNCT02032836Phase 1/2
• Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension PatientsCompletedNCT01781052
• Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT SystemCompletedNCT01468545
• Efficacy of Ventavis Used in Real-life Setting.CompletedNCT01355380
• An Open Multiple Dose Titration Study In Patients With Pulmonary HypertensionCompletedNCT00454558Phase 2